Application of ATIC overexpression method in promotion of myocardial cell proliferation
The cardiomyocyte cycle is regulated through the overexpression method of ATIC, which solves the problem of insufficient proliferation of cardiomyocytes, and achieves significant proliferation of cardiomyocytes and enhances the potential of cardiomyocytes without affecting cardiac function.
Patent Information
- Application Number
- CN202410787019.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-18
- Publication Date
- 2024-11-22
AI Technical Summary
The existing technology cannot effectively promote cardiomyocyte proliferation. The treatment of cardiovascular disease mainly delays the development of the disease and cannot reverse myocardial injury. The regulatory mechanism of cardiac regeneration therapy is unclear.
The cardiomyocyte cycle is regulated by overexpression of ATIC. As an important target for promoting cardiomyocyte proliferation, ATIC is overexpressed or knocked down ATIC in cardiomyocytes using plasmid vectors and lentiviral technology to regulate its proliferation ability.
Overexpression of ATIC can significantly improve the proliferation ability of cardiomyocytes, increase cell number and DNA synthesis, reduce binuclear cells, increase the expression of proliferation markers, and basically do not affect cardiac function, providing new methods for cardiomyocyte proliferation and cardiac regeneration therapy. Potential strategies.
Smart Images

Figure CN118995810A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to application of a method for overexpressing ATIC in promoting cardiomyocyte proliferation. Background Art
[0002] Cardiac regeneration research has always been a hot topic in the field of heart disease treatment. Human cardiomyocytes (CM) exit the cell cycle shortly after birth and are difficult to enter the repair pathway after injury. It is currently believed that CM damage is irreversible, and cardiovascular diseases (CVD) such as myocardial infarction, coronary heart disease and angina pectoris can lead to a large number of CM losses, which in turn deteriorate into heart failure.
[0003] Gene medicine is a method of using a suitable medium carrier to transduce normal or therapeutic exogenous genes into target cells to replace or correct pathogenic genes. The target gene is integrated into the target cell chromosome, or is not integrated and located outside the chromosome, but can be transcribed and translated in the cell, changing the original gene expression of the cell in order to achieve the purpose of treating the disease. However, existing gene medicines do not involve cardiovascular diseases or focus on promoting cardiomyocyte proliferation. At present, the clinical treatment strategy for cardiovascular diseases is still mainly to delay the development of the disease, and it is impossible to reverse the disease process. The core of cardiac regenerative therapy is to rebuild the myocardium, that is, by regulating the signal pathways of the CM cycle, stimulating the ability of existing CM to produce new CM, thereby meeting the core standards of cardiac repair, while myocardial regeneration faces the problem of unclear regulatory mechanisms. Summary of the invention
[0004] In view of the above technical problems, the present invention provides an application of a method for overexpressing ATIC in promoting cardiomyocyte proliferation. The present invention first discovered that overexpression of ATIC can enhance the original proliferation capacity of cardiomyocytes without substantially affecting cardiac function.
[0005] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical solutions:
[0006] The first aspect of the present invention provides an application of a method for overexpressing ATIC in promoting cardiomyocyte proliferation.
[0007] ATIC, i.e. AICAR formyltransferase / IMP cyclohydrolase (5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase / IMP Cyclohydrolase), is a bifunctional protease that catalyzes the last two steps of the de novo purine biosynthesis pathway. The present invention first discovered through experimental research that after transfection of neonatal rat primary cardiomyocytes (NRCM) with a plasmid-borne ATIC overexpression vector, the mRNA and protein levels of ATIC in the cells increased significantly, the number of cells increased significantly, DNA synthesis, cardiomyocyte mitosis and cytokinesis increased significantly, binuclear NRCM decreased significantly, proliferation markers Cyclin D1 and PCNA expression increased, and the levels of cell cycle protein markers of all cell division cycles increased, indicating that ATIC can independently regulate the cardiomyocyte cycle and thus change the proliferation ability of NRCM. The present invention also verified the regulatory effect of ATIC on in vivo cardiomyocytes by knocking down ATIC with a lentivirus, and found that after the administration of the lentivirus, the mRNA and protein levels of ATIC were significantly decreased, the number of NRCMs was significantly reduced, the DNA synthesis of NRCMs, cardiomyocyte mitosis and cytokinesis were significantly reduced, the binuclear NRCMs were significantly increased, the expression of proliferation markers Cyclin D1 and PCNA was reduced, and the levels of cell cycle protein markers in all cell division cycles were reduced. The above experiments prove that ATIC can be used as an important target for promoting cardiomyocyte proliferation, and overexpression of ATIC can be used to promote cardiomyocyte proliferation, such as promoting cardiomyocyte proliferation in vitro, using reagents that promote overexpression of ATIC to prepare products that promote cardiomyocyte proliferation, and using reagents that detect ATIC to prepare reagents for diagnosing cardiomyocyte proliferation.
[0008] In combination with the first aspect, the application is application in promoting cardiomyocyte proliferation in vitro.
[0009] Preferably, the cardiomyocytes are rat cardiomyocytes, and more preferably, they are primary cardiomyocytes of neonatal rats.
[0010] In combination with the first aspect, the method for overexpressing ATIC may adopt the following operations: constructing an ATIC overexpression plasmid, and transferring the ATIC overexpression plasmid into cardiomyocytes.
[0011] Preferably, the method for constructing the ATIC overexpression plasmid is: using a plasmid vector as a template, performing PCR amplification with an upstream primer having a sequence as shown in SEQ ID No. 1 and a downstream primer having a sequence as shown in SEQ ID No. 2, exchanging the obtained amplification primers into a linearized expression vector, identifying the obtained recombinant clones, and screening out positive transformants.
[0012] The second aspect of the present invention provides use of an agent for promoting overexpression of ATIC in the preparation of a product for promoting proliferation of cardiomyocytes.
[0013] Preferably, the reagents include reagents for constructing an ATIC overexpression plasmid and reagents for transferring the ATIC overexpression plasmid into cardiomyocytes.
[0014] Preferably, the reagents for constructing the ATIC overexpression plasmid include an upstream primer with a sequence as shown in SEQ ID No. 1, a downstream primer with a sequence as shown in SEQ ID No. 2, and a template.
[0015] Preferably, the product that promotes cardiomyocyte proliferation is a gene drug for cardiac regenerative therapy.
[0016] A third aspect of the present invention provides use of a reagent for detecting ATIC in preparing a reagent for diagnosing cardiomyocyte proliferation.
[0017] The beneficial effects of the present invention are as follows: the present invention first discovered that ATIC is an effective target for promoting cardiomyocyte proliferation, and experimentally verified that overexpression of ATIC can independently regulate the cardiomyocyte cycle so as to enhance the original proliferation capacity of cardiomyocytes, and basically does not affect cardiac function. Therefore, the method of overexpressing ATIC can be used to promote cardiomyocyte proliferation. Promoting cardiomyocyte proliferation in vitro by overexpressing ATIC can provide a new method for obtaining cardiomyocytes, and can provide assistance or new targets for screening new drugs that promote cardiomyocyte proliferation. In addition, according to the concept of promoting cardiomyocyte proliferation by overexpression of ATIC, reagents that promote overexpression of ATIC can also be used to prepare products that promote cardiomyocyte proliferation, such as making a kit that promotes overexpression of ATIC into a kit that promotes cardiomyocyte proliferation in vitro, or making a reagent that promotes overexpression of ATIC into a gene drug that promotes cardiomyocyte proliferation and is suitable for cardiac regeneration therapy. Moreover, based on this concept, reagents for detecting ATIC can also be used to prepare reagents for diagnosing cardiomyocyte proliferation. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 The mRNA and protein levels of ATIC and the expression levels of proliferation markers Cyclin D1 and PCNA in Example 1 of the present invention;
[0019] Figure 2 is the number of NRCMs in Example 1 of the present invention;
[0020] Figure 3 The DNA synthesis, cardiomyocyte mitosis and cytokinesis of NRCM in Example 1 of the present invention;
[0021] Figure 4is the number of dual-core NRCMs in Example 1 of the present invention;
[0022] Figure 5 is the level of cell cycle protein markers of the cell division cycle in Example 1 of the present invention;
[0023] Figure 6 The structure of compound 14 in Example 1 of the present invention;
[0024] Figure 7 is the ATIC protein level and the expression levels of proliferation markers Cyclin D1 and PCNA in NRCMs treated with Cpd14 in Example 1 of the present invention;
[0025] Figure 8 is the number of NRCMs treated with Cpd14 in Example 1 of the present invention;
[0026] Fig. 9 is the number of myocardial cells positive for proliferation markers EdU, pH3, and Aurora B after treatment with Cpd14 in Example 1 of the present invention;
[0027] Fig.10 is the number of binuclear NRCMs treated with Cpd14 in Example 1 of the present invention;
[0028] Fig.11 is the level of p21 and p27 after treatment with Cpd14 in Example 1 of the present invention;
[0029] Fig.12 is the cell cycle protein mRNA level during the cell proliferation period after treatment with Cpd14 in Example 1 of the present invention;
[0030] Fig.13 The mRNA and protein levels of ATIC and the expression levels of proliferation markers Cyclin D1 and PCNA in Example 2 of the present invention;
[0031] Fig.14 is the number of NRCMs in Example 2 of the present invention;
[0032] Fig.15 The DNA synthesis, myocardial cell mitosis and cytokinesis in Example 2 of the present invention;
[0033] Fig.16 is the number of dual-core NRCMs in Example 2 of the present invention;
[0034] Fig.17 is the level of cell cycle protein markers of the cell division cycle in Example 2 of the present invention;
[0035] Fig.18is the ATIC protein level in the neonatal mouse cardiomyocytes and the adult mouse cardiomyocytes in Example 2 of the present invention;
[0036] Fig.19 is the expression level of ATIC in the mouse model overexpressing ATIC in Example 2 of the present invention;
[0037] Fig. 20 is the cardiac function of the mouse model overexpressing ATIC in Example 2 of the present invention;
[0038] Fig.21 This is a photo of the heart and HE staining of the mouse model overexpressing ATIC in Example 2 of the present invention;
[0039] Fig. 22 is the HW / BW of the mouse model overexpressing ATIC in Example 2 of the present invention;
[0040] Fig.23 is the left ventricular mass of the mouse model overexpressing ATIC in Example 2 of the present invention;
[0041] Fig.24 is the average area of cardiomyocytes in the mouse model overexpressing ATIC in Example 2 of the present invention;
[0042] Fig.25 is the number of cardiac DNA synthesis, cardiomyocyte mitosis and cytokinesis marker-positive cardiomyocytes in the mouse model overexpressing ATIC in Example 2 of the present invention;
[0043] Fig.26 is the level of proliferation marker protein in the mouse model overexpressing ATIC in Example 2 of the present invention;
[0044] Fig. 27 It is a cell cycle protein of the mouse model overexpressing ATIC in Example 2 of the present invention. DETAILED DESCRIPTION
[0045] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work fall within the scope of protection of the present invention.
[0046] It is difficult for cardiomyocytes (CMs) to enter the repair pathway after injury. Cardiovascular diseases such as myocardial infarction, coronary heart disease, and angina pectoris can lead to the loss of a large number of CMs, which then deteriorate into heart failure. At present, the clinical treatment strategy for cardiovascular diseases is still mainly to delay the progression of the disease, and it is impossible to reverse the disease process. Cardiac regenerative therapy is to stimulate the ability of existing CMs to produce new CMs by regulating the signaling pathways of the CM cycle, thereby achieving myocardial reconstruction, but the regulatory mechanism of myocardial regeneration is still unclear.
[0047] The present invention is based on the first discovery that ATIC is an effective target for promoting cardiomyocyte proliferation. Overexpression of ATIC can independently regulate the cardiomyocyte cycle to enhance the original proliferation capacity of cardiomyocytes without substantially affecting cardiac function. Based on this, the present invention provides an application of a method for overexpressing ATIC in promoting cardiomyocyte proliferation.
[0048] The following is further described with reference to specific embodiments.
[0049] Example 1
[0050] In this example, primary cardiomyocytes of neonatal rats were used to verify the regulatory effect of ATIC on cardiomyocytes.
[0051] 1. Construction of Atic overexpression vector (plasmid)
[0052] Target gene name: Atic (NM_031014);
[0053] Species: SD newborn rats (1-3 days old);
[0054] Plasmid vector (constructed by GeneCare Gene Corporation) name: GV740;
[0055] Element sequence: CMV enhancer-MCS-3flag-polyA-EF1A-mCherry-sv40-puromycin;
[0056] Cloning site: BamHI / KpnI;
[0057] The vector was digested by enzymes and then tested for quality and then used for subsequent PCR amplification and detection.
[0058] The target gene and vector sequence were amplified by PCR using the upstream primer Atic (94439-1) -p1 with a sequence as shown in SEQ ID No. 1 and the downstream primer Atic (94439-1) -p2 with a sequence as shown in SEQ ID No. 2. The PCR reaction system is shown in Table 1, and the PCR reaction conditions are shown in Table 2.
[0059] Upstream amplification primer Atic(94439-1)-p1:
[0060] CACACTGGACTAGTGGATCCCGCCACCATGGCTTCCTCCCAGCTTGC;
[0061] Downstream amplification primer Atic (94439-1)-p2:
[0062] AGTCACTTAAGCTTGGTACCGAGTGGTGGAAGAGACGCAGATCTG.
[0063] Table 1 PCR reaction system
[0064] Reagents Volume (μL) <![CDATA[ddH 2 The]]> 32.5 5×PS Buffer 10 dNTP Mix (2.5 mM each) 4 Upstream amplification primer (10 μM) 1 Downstream amplification primer (10 μM) 1 Template (10 ng / μL) 1 PrimeSTAR HSDNApolymerase 0.5 total 50
[0065] The template source is the plasmid vector GV740 after enzyme digestion.
[0066] Table 2 PCR reaction conditions
[0067]
[0068] The size of the PCR product was 1825 kb.
[0069] Exchange the PCR product into the linearized expression vector. Prepare the identification reaction system shown in Table 3 with primers KL94439-p3 and KL94439-p4, shake and mix, and centrifuge briefly. In the clean bench, pick a single colony with a sterile pipette tip into 20 μL of the identification system, pipette and mix, place in a PCR instrument for reaction, and identify the recombinant clone. The identification reaction conditions are shown in Table 4.
[0070] Upstream primer KL94439-p3: TTGTTGACAAGTCGTTGTTT;
[0071] Downstream primer KL94439-p4: CAGCCTATTTTGCTAGTTTG.
[0072] Table 3 Identification reaction system
[0073] Reagents Volume (μL) <![CDATA[ddH 2 The]]> 9.2 2×Taq Plus Master Mix 10 Upstream primer (10 μM) 0.4 Downstream primer (10 μM) 0.4 total 20
[0074] Table 4 Identification reaction conditions
[0075]
[0076] After identification, the size of the PCR product of the positive transformant was 721 kb.
[0077] The positive clone was sequenced and its nucleotide sequence was:
[0078] AGAATTCCACCACACTGGACTAGT GGATCC CGCCACCATGGCTTCCTCCCAGCTTGCCCTGTTCAGTGTGTCTGACAAAACTGGCCTCGTGGAATTTGCCAGAAACCTCGCGTCTCTTGGTTTGAGTTTGGTCGCTTCTGGAGGCACGGCAAAAGCGATCAGGGATGCTGGCCTGGCAGTGAGAGATGTGTCTGAGCTAACTGGGTTCCCTGAAATGTTAGGGGGGCGTGTGAAAACCTTGCATCCTGCAGTCCATGCTGGAATCTTAGCACGCAATATTCCAGAAGATGCTGCTGACATGGCCAGGCTTGATTTCAACCTCATAAGAGTTGTTGTCTGTAACCTGTACCCGTTCGTGAAGACTGTGGCTTCTCCAGATGTAACCGTTGAGGCAGCTG
[0079] TTGAGCAAATTGACATTGGTGGCGTGACCTTACTGAGAGCTGCAGCCAAA
[0080] AACCATGCTCGAGTGACAGTTGTGTGTGAGCCAGAGGACTATGGTGCGGT
[0081] GGCTGCAGAGATGCAGGGCTCTGGTAATAAGGACACCTCCCTGGAGACC
[0082] AGGCGCCACTTGGCATTGAAGGCATTCACGCATACCGCTCAATATGATGAA
[0083] GCGATTTCGGATTACTTCAGGAGACAGTACAGTAAAGGAATTTCTCAGAT
[0084] GCCCTTGAGGTATGGGATGAACCCCCATCAGACTCCTGCCCAGCTGTATAC
[0085] ACTGAAGCCCAAGCTTCCCATCACAGTTCTCAACGGAGCCCCAGGATTCA
[0086] TAAACCTCTGCGATGCTTTGAATGCCTGGCAGCTGGTGACAGAGCTGAGA
[0087] GGAGCAGTAGACATTCCAGCTGCGGCGTCTTTTCAAGCACGTCAGCCCCAGC
[0088] AGGTGCTGCTGTTGGGTTCCACTCAGTGAGGACGAAGCCAGATCTGC
[0089] ATGGTCTATGACCTCTATCCGACCCTCACGCCCCTGGCCATTGCATATGCA
[0090] AGAGCAAGAGAGCTGATAGGATGTCTTCATTGGTGATTTTGTTGCATTA
[0091] TCTGATGTTTGTGATGTCCCAACTGCAAAATTATTCTCCAGAGAAGTGTCA
[0092] GATGGTATTGTTGCCCAGGATATGAGGAAGAGGCCTTGAAATACTTTCT
[0093] AAAAAAAAAAATGGAAAGCTACTGTGTTCTTCAGATGGACCAGTCCTACAA
[0094] ACCGGATGAAAATGAAGTTCGAACGCTCTTTGGTCTTCGTTTAAGCCAGA
[0095] AGAGAAATAATGGTGTTGTTGACAAGTCGTTGTTTAGCAAATTGTCACCA
[0096] AGAATAAGATCTGCCGGAATCTGCTCTCCGAGACCTCATTGTCGCCACC
[0097] ATCGCTGTCAAGTATACTCAGTCTAATTCGGTGTGCTATGCCAAGGACGGG
[0098] CAGGTTATTGGCATCGGAGCAGGACAGCAGTCTCGGATACACTGTACACG
[0099] CCTTGCAGGTGATAAGGCAAACTCTTGGTGGCTTCGGCACCCATCCACGAG
[0100] TGCTTTCCATGAAGTTTTAAAGCTGGGGTGAAGAGAGCAGAAGTCTCCAAT
[0101] GCCATCGATCAGTATGTGACCGGCACCATTGGTGAGGGTGAAGACCTGGT
[0102] GAAATGGAAAGCACTGTTTGAAGAGGTTCCTGAGTTACTCACTGAGGCG
[0103] GAGAAGAAGGAATGGGTGGACAAGCTGAGTGGCGTGTCTGTCAGTTCCG
[0104] ATGCTTTCTTCCTTTCAGGGATAATGTAGACCGAGCGAAAAGGAGTGGT
[0105] GTGGCCTACATTGTTGCTCCATCCGGATCTACTGCTGACAAGGTTGTGATC
[0106] GAGGCGTGTGACGAGCTGGGGATCGTGTTGGCTCATACAGATCTGCGTCT
[0107] CTTCCACCACTC GGTACC AAGCTTAAGTGACTACAAGGATGA.
[0108] The sequencing results of the positive clones confirmed that the product was authentic.
[0109] To 3~4×10 6 8 μg p-Ctrl-Atic was administered to primary cardiomyocytes of neonatal rats (add four times the volume of transfection reagent and 250 μl opti-MEM medium, mix well and incubate at room temperature for 5 min, then mix the mixture with 250 μl opti-MEM medium containing p-Ctrl / Atic and incubate at room temperature for 20 min). After 6 h, the medium was changed to normal medium. After 48 h, the cells were obtained for subsequent PCR, western blot and immunofluorescence experiments. The results are shown in Figures 1 to 5 As shown. The mRNA and protein levels of ATIC increased significantly (as shown Figure 1 Compared with shRNA-Ctrl, the number of cells increased significantly (as shown in Figure 2 The original proliferation capacity was improved, which was reflected in the significant increase of DNA synthesis, cardiomyocyte mitosis and cytokinesis of NRCM (as shown in Figure 3The binuclear NRCM was significantly reduced (as shown). Figure 4 ), the expression of proliferation markers Cyclin D1 and PCNA increased (as shown Figure 1 ), the levels of cell cycle markers of all cell division cycles increased (as shown in Figure 5 The above results indicate that ATIC can independently regulate the cardiomyocyte cell cycle and thus change the proliferation capacity of NRCMs.
[0110] 2. Further administration of compound 14 (Cpd14) (such as Figure 6 Western blot results showed that the ATIC protein level in NRCMs treated with Cpd14 was significantly decreased (as shown in Figure 2A). Figure 7 The number of cells decreased significantly (as shown in Figure 8 The number of myocardial cells positive for proliferation markers EdU, pH3, and Aurora B was significantly reduced (as shown in Fig. 9 As shown), the dual-core NRCM increases (as shown Fig.10 The expression levels of proliferation markers Cyclin D1 and PCNA decreased (as shown in Figure 7 PCR showed that p21 and p27 levels increased (as shown Fig.11 ), the mRNA levels of cell cycle proteins in all cell proliferation stages were significantly reduced (as shown in Fig.12 shown).
[0111] 3. Construction of Atic overexpression vector (lentiviral packaging shRNA)
[0112] Target gene name: Atic (NM_031014);
[0113] Species: SD newborn rats (1-3 days old);
[0114] Easy-siRNA design is shown in Table 5:
[0115] Table 5 Easy-siRNA design
[0116]
[0117] Plasmid vector (constructed by GeneCare Gene Corporation) name: GV298;
[0118] Component sequence: U6-MCS-Ubiquitin-Cherry-IRES-puromycin;
[0119] Cloning site: Age I / EcoR I;
[0120] Control number: CON207;
[0121] Control insert sequence: TTCTCCGAACGTGTCACGT;
[0122] The synthetic oligo information is shown in Table 6:
[0123] Table 6 Synthetic oligo information
[0124]
[0125] The positive clone was sequenced and its nucleotide sequence was:
[0126]
[0127] The sequencing results of the positive clones confirmed that the product was authentic.
[0128] To 3~4×10 6 Primary cardiomyocytes were given 5 μl LV-Ctrl / Atic (titer 10 8 , mixed with 20 μl inducer P), and cells were obtained after 72 h for subsequent PCR, western blot and immunofluorescence experiments. The results are shown in Figures 13 to 17 As shown in Figure 2, the mRNA and protein levels of ATIC decreased significantly (e.g. Fig.13 ), the number of NRCMs decreased significantly (as shown in Fig.14 The normal proliferation capacity was significantly inhibited, which was reflected in the significant reduction of DNA synthesis, cardiomyocyte mitosis and cytokinesis in NRCM (as shown in Fig.15 As shown), the dual-core NRCM increased significantly (as shown Fig.16 The expression of proliferation markers Cyclin D1 and PCNA decreased (as shown in Fig.13 ), and the levels of cell cycle markers of all cell division cycles decreased (as shown in Fig.17 shown).
[0129] Example 2
[0130] This example uses the mouse heart in vivo to verify the regulatory effect of ATIC on cardiomyocytes.
[0131] 1. Western blot test was performed on the cardiomyocytes of newborn mice and adult mice. The results of Western blot showed that the level of ATIC protein in the cardiomyocytes of newborn mice was significantly higher than that in the cardiomyocytes of adult mice (e.g. Fig.18 shown).
[0132] 1. Construction of adeno-associated virus vector (AAV9) for overexpression
[0133] Target gene name: Atic (NM_026195);
[0134] Species: C57 / 6J mice;
[0135] Plasmid vector (constructed by GeneCare Gene Corporation) name: GV425;
[0136] Element sequence: cTNT promoter-EGFP-FT2A-MCS-WPRE-SV40 polyA;
[0137] Cloning site: BamHI / SacII;
[0138] The target gene and vector sequence were amplified by PCR using the upstream primer Atic (97952-S1) -p1 and the downstream primer Atic (97952-S1) -p2. The PCR reaction system is shown in Table 7, and the PCR reaction conditions are shown in Table 8.
[0139] Upstream amplification primer Atic(97952-S1)-p1:
[0140] CCGGCCCTTCTAGAGGATCCATGGCCTCGTCTCAGCTTGCCCTG;
[0141] Downstream amplification primer Atic (97952-S1)-p2:
[0142] GGTTGATTATCTTACCGCGGTCAGTGGTGGAAGAGCCGGAGATC.
[0143] Table 7 PCR reaction system
[0144] Reagents Volume (μL) <![CDATA[ddH 2 The]]> 33.3μL <![CDATA[5×PS Buffer(Mg 2+ plus)]]> 10μL dNTP Mix (2.5 mM each) 4μL Upstream amplification primer (10 μM) 1μL Downstream amplification primer (10 μM) 1μL Template (200ng / μL) 0.2μL PrimeSTAR HSDNApolymerase(2.5U / μL) 0.5μL total 50μL
[0145] The template source is the plasmid vector GV425 after enzyme digestion.
[0146] Table 8 PCR reaction conditions
[0147]
[0148] The size of the PCR product was 1819 kb.
[0149] Exchange the PCR product into the linearized expression vector. Prepare the identification reaction system shown in Table 9 with primers KL97952-p3 and KL97952-p4, shake and mix, and centrifuge briefly. In the clean bench, pick a single colony with a sterile pipette tip into 20 μL of the identification system, pipette and mix, place in a PCR instrument for reaction, and identify the recombinant clone. The identification reaction conditions are shown in Table 10.
[0150] Upstream primer KL97952-p3:TCGTTGACAAGTCATTATTT;
[0151] Downstream primer KL97952-p4: CAATAGCATGATACAAAGGC.
[0152] Table 9 Identification reaction system
[0153]
[0154]
[0155] Table 10 Identification reaction conditions
[0156]
[0157] After identification, the size of the PCR product of the positive transformant was 724 kb.
[0158] The positive clone was sequenced and its nucleotide sequence was:
[0159] GAGGAGAATCCCGGCCCTTCTAGA GGATCC CCGCGG TAAGATAATCAACCTCTGGATTAC.
[0160] The sequencing results of the positive clones confirmed that the product was authentic.
[0161] 5×10 11 The titer of μg / ml was injected into the heart of adult mice, 5μl / site, and 3-4 sites were injected in the left ventricle. The heart was obtained one month later for subsequent PCR, western blot and immunofluorescence experiments. The results are shown in Figures 19 to 17 As shown: Western blot results showed that ATIC expression levels increased (such as Fig.19 As shown in the figure, the model was successfully constructed; the results of cardiac ultrasound showed that the cardiac function was not affected after overexpression of ATIC (as shown in the figure Fig. 20 Heart morphology and HE staining showed that the left ventricle of the mouse heart was significantly enlarged after overexpression of ATIC (as shown in Fig.21 As shown), HW / BW increases (as Fig. 22 ), there is a tendency for left ventricular mass to increase (as shown Fig.23 WGA staining showed that the average area of myocardial cells was significantly reduced (as shown in Fig.24 The number of cardiac DNA synthesis, cardiomyocyte mitosis and cytokinesis marker-positive cardiomyocytes in mice overexpressing ATIC increased significantly (as shown in Fig.25 ), and the levels of proliferation marker proteins were upregulated (as shown in Fig.26 Cell cycle proteins are mainly upregulated during mitosis (as shown in Fig. 27 shown).
[0162] It can be seen from the results of Example 1 and Example 2 that ATIC can be used as an important target for promoting cardiomyocyte proliferation, and its overexpression does not affect normal cardiac function.
[0163] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. Application of the method of overexpressing ATIC in promoting cardiomyocyte proliferation.
2. The use according to claim 1, characterized in that: The application is application in promoting the proliferation of cardiomyocytes in vitro.
3. The use according to claim 2, characterized in that: The cardiomyocytes are rat cardiomyocytes.
4. The use according to any one of claims 1 to 3, characterized in that: The method for overexpressing ATIC adopts the following operations: constructing an ATIC overexpression plasmid, and transferring the ATIC overexpression plasmid into cardiomyocytes.
5. The use according to claim 4, characterized in that: The method for constructing the ATIC overexpression plasmid is as follows: using a plasmid vector as a template, performing PCR amplification with an upstream primer having a sequence as shown in SEQ ID No. 1 and a downstream primer having a sequence as shown in SEQ ID No. 2, exchanging the obtained amplification primers into a linearized expression vector, identifying the obtained recombinant clones, and screening out positive transformants.
6. Use of reagents that promote ATIC overexpression in the preparation of products that promote cardiomyocyte proliferation.
7. The use according to claim 6, characterized in that: The reagents include reagents for constructing an ATIC overexpression plasmid and reagents for transferring the ATIC overexpression plasmid into cardiomyocytes.
8. The use according to claim 7, characterized in that: The reagents for constructing the ATIC overexpression plasmid include an upstream primer with a sequence as shown in SEQ ID No. 1, a downstream primer with a sequence as shown in SEQ ID No. 2, and a template.
9. The use according to claim 6, characterized in that: The product that promotes myocardial cell proliferation is a gene drug for cardiac regeneration therapy.
10. Use of reagents for detecting ATIC in the preparation of reagents for diagnosing cardiomyocyte proliferation.
